AM0010 Publications

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, online ahead of print August 15, 2016.  Go to Link

See related article, Understanding the Pathway: Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy, Journal of Clinical Oncology, online ahead of print August 29, 2016. Go to Link

PEG-rIL-10 treatment decreases FoxP3+ Tregs despite upregulation of intratumoral IDO. OncoImmunology, Volume 5, 2016 - Issue 7. Go to Link

PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia. PLoS ONE. 11(6): e0156229. doi:10.1371/journal.pone.0156229. View PDF  Go to Link

IL-10: Expanding the immune oncology horizon. Receptor Clin Invest 2015; 2: e1041. doi: 10.14800/rci.1041. Go to Link

The Potentiation of IFN╬│ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells. Journal of Interferon & Cytokine Research, online ahead of print August 26, 2015. Go to Link

Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity. Cancer Immunology Research 2(3): 194-199, March 2014.

Pegylated IL-10 induces cancer immunity. Bioessays 35: 623-631, 2013.

IL-10 Elicits IFN-gamma Dependent Tumor Surveilance. Cancer Cell 20: 781-796, December 13, 2011.